bioAffinity Tech SEC Filings

bioAffinity Technologies, Inc. (BIAF) filed an 8-K reporting that it furnished a press release containing financial information for the quarter ended September 30, 2025. The company stated the press release is provided under Item 2.02 and is furnished, not filed, and will not be incorporated by reference into other SEC filings.

Exhibits include 99.1 (the press release dated November 14, 2025) and 104 (Cover Page Interactive Data File). The company’s securities listed are Common Stock (BIAF) and Tradeable Warrants (BIAFW) on The Nasdaq Stock Market LLC.

bioAffinity Technologies (BIAF) called a Special Meeting to approve multiple share-related actions. The Board asks stockholders to approve: issuing up to 271,500 shares upon exercise of August 2025 warrants; a warrant anti-dilution reset that could raise the exercisable amount up to 365,620 shares; and a Series B Preferred anti-dilution reset allowing up to 131,884 additional conversion shares. The Board also seeks to amend the 2024 Equity Incentive Plan to 750,000 shares from 66,666; authorize one or more non-public offerings of up to 10 million shares for up to $10,000,000 (at discounts up to 35%) through December 31, 2026; approve any Nasdaq Rule 5635 change of control arising from such offerings; and permit adjournment if needed.

As context, shares outstanding were 3,633,815 as of November 4, 2025. The company states the August 2025 warrants, if exercised for cash, could provide up to approximately $2.9 million in gross proceeds. The Board recommends “FOR” on all proposals.

bioAffinity Technologies (BIAF) filed an 8‑K announcing month‑over‑month growth in CyPath® Lung test volume. The company disclosed the update under Item 8.01 (Other Events) and furnished a detailed press release as Exhibit 99.1. The filing identifies the company’s listed securities on the Nasdaq Capital Market under symbols BIAF (common stock) and BIAFW (warrants). The report date is November 5, 2025.

bioAffinity Technologies reported that the Australian Patent Office has accepted its patent application AU 2019253111, titled “System and Method for Determining Lung Health.” The patent covers methods that combine flow cytometry with fluorescent probes and molecular tags that attach to specific cell types to detect cellular and molecular signatures of multiple lung diseases. The company issued a press release, attached as Exhibit 99.1.

bioAffinity Technologies (BIAF) called a Special Meeting to seek stockholder approval for multiple equity actions. The agenda includes authorizing the issuance of up to 271,500 shares upon exercise of August 2025 warrants, approving an anti-dilution reset that could raise the warrant share count by up to 365,620, and approving a similar anti-dilution reset for Series B Preferred that could add up to 131,884 conversion shares.

The Company also asks to amend its 2024 Equity Incentive Plan to increase the reserve to 750,000 shares and to authorize one or more non‑public offerings of up to 10 million shares for total consideration not exceeding $10,000,000, at discounts up to 35%, through December 31, 2026, along with related change‑of‑control approval under Nasdaq rules. Shares outstanding were 3,633,815 as of the record date. The Board recommends voting “FOR” each proposal.

bioAffinity Technologies reported it will present new research at CHEST 2025, the annual meeting of the American College of Chest Physicians. The company’s project manager for product development, Rossella Titone, PhD, will present the poster titled “The Effect of Sputum Storage and Shipping Temperature on Flow Cytometric Outcomes of Sputum-Based Diagnostic Tests.”

The presentation is scheduled for October 22, 2025 at 10:20 a.m. at poster board #4324. The company attached its press release and the full poster as Exhibits 99.1 and 99.2, which are incorporated by reference.

bioAffinity Technologies (BIAF) reported a regulatory milestone. The company received a notification of allowance from the U.S. Patent and Trademark Office for a patent titled “Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning.” The patent covers a system and method for predicting the likelihood of lung cancer by analyzing patient sputum samples.

The company disclosed the news in a Form 8-K under Item 8.01 and attached a related press release as Exhibit 99.1. A notification of allowance indicates the USPTO intends to grant the patent following completion of administrative steps.

bioAffinity Technologies announced it has regained compliance with Nasdaq listing standards. A Nasdaq Hearings Panel found the company in compliance with Listing Rule 5550(a)(2) (the Minimum Bid Price Rule) and 5550(b)(1) (the Minimum Stockholders’ Equity Rule).

The company will be under a mandatory panel monitor for one year. If, during that period, it falls out of compliance with the Minimum Stockholders’ Equity Rule, it will not be granted additional time to regain compliance, though it may request a new hearing before any delisting. The company issued a press release on October 15, 2025, noting the compliance status.